Quoin Pharmaceuticals Loss per ADS of -$0.94 beats by $0.41

Nov. 10, 2022 10:00 AM ETQuoin Pharmaceuticals, Ltd. (QNRX)By: Ahmed Farhath, SA News Editor
  • Quoin Pharmaceuticals press release (NASDAQ:QNRX): Q3 Loss per ADS of -$0.94 beats by $0.41.
  • Ended Q3 with ~$15.2M in cash and marketable securities.
  • Ongoing clinical study for QRX003 in Netherton Syndrome continues to progress, with a majority of clinical sites now fully open and the remaining sites on target to open in Q4 2022.
  • Q3 total operating expenses $2.3M vs $1.3M.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.